Lenalidomide as a disease-modifying agent in patients with del(5q) myelodysplastic syndromes: linking mechanism of action to clinical outcomes

TP53mutations in myelodysplastic syndrome are strongly correlated with aberrations of chromosome 5, and correlate with adverse prognosis

(2013) Austin G. Kulasekararaj et al.   BRITISH JOURNAL OF HAEMATOLOGY

Multiple inhibitory ligands induce impaired T-cell immunologic synapse function in chronic lymphocytic leukemia that can be blocked with lenalidomide: establishing a reversible immune evasion mechanism in human cancer

(2012) A. G. Ramsay et al.   BLOOD

Lenalidomide for Treatment of Myelodysplastic Syndromes

(2012) Rami S. Komrokji et al.   CURRENT PHARMACEUTICAL DESIGN

Correlation of clinical response and response duration with miR-145 induction by lenalidomide in CD34+ cells from patients with del(5q) myelodysplastic syndrome

(2012) C. P. Venner et al.   HAEMATOLOGICA

Topography, Clinical, and Genomic Correlates of 5q Myeloid Malignancies Revisited

(2012) Andres Jerez et al.   JOURNAL OF CLINICAL ONCOLOGY

Survival, prognostic factors and rates of leukemic transformation in 381 untreated patients with MDS and del(5q): A multicenter study

(2012) U Germing et al.   LEUKEMIA

Lenalidomide does not increase AML progression risk in RBC transfusion-dependent patients with Low- or Intermediate-1-risk MDS with del(5q): a comparative analysis

(2012) A Kuendgen et al.   LEUKEMIA

Lenalidomide promotes p53 degradation by inhibiting MDM2 auto-ubiquitination in myelodysplastic syndrome with chromosome 5q deletion

(2012) S Wei et al.   ONCOGENE

Dexamethasone and lenalidomide have distinct functional effects on erythropoiesis

(2011) A. Narla et al.   BLOOD

A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with del5q

(2011) P. Fenaux et al.   BLOOD

Treatment with lenalidomide does not appear to increase the risk of progression in lower risk myelodysplastic syndromes with 5q deletion. A comparative analysis by the Groupe Francophone des Myelodysplasies

(2011) L. Ades et al.   HAEMATOLOGICA

TP53 Mutations in Low-Risk Myelodysplastic Syndromes With del(5q) Predict Disease Progression

(2011) Martin Jädersten et al.   JOURNAL OF CLINICAL ONCOLOGY

58 Interaction of karyotype complexity and response on overall survival and AML progression in lenalidomide-treated Low/INT-1 risk del (5q) MDS patients

(2011) A. Giagounidis et al.   LEUKEMIA RESEARCH

Biology and treatment of the 5q- syndrome

(2011) Eric Padron et al.   Expert Review of Hematology

The Apcmin mouse has altered hematopoietic stem cell function and provides a model for MPD/MDS

(2010) S. W. Lane et al.   BLOOD

Induction of p53 and up-regulation of the p53 pathway in the human 5q- syndrome

(2010) A. Pellagatti et al.   BLOOD

Advances in the 5q- syndrome

(2010) J. Boultwood et al.   BLOOD

Haploinsufficiency of Apc leads to ineffective hematopoiesis

(2010) J. Wang et al.   BLOOD

Haploinsufficiency for ribosomal protein genes causes selective activation of p53 in human erythroid progenitor cells

(2010) S. Dutt et al.   BLOOD

Ribosomopathies: human disorders of ribosome dysfunction

(2010) A. Narla et al.   BLOOD

Changes in RPS14 expression levels during lenalidomide treatment in Low- and Intermediate-1-risk myelodysplastic syndromes with chromosome 5q deletion

(2010) Esther N. Oliva et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

Pleiotropic mechanisms of action of lenalidomide efficacy in del(5q) myelodysplastic syndromes

(2010) Carla Heise et al.   Expert Review of Anticancer Therapy

Pathophysiology and treatment of the myelodysplastic syndrome with isolated 5q deletion

(2010) M. Jadersten   HAEMATOLOGICA

Cytogenetic follow-up by karyotyping and fluorescence in situ hybridization: implications for monitoring patients with myelodysplastic syndrome and deletion 5q treated with lenalidomide

(2010) G. Gohring et al.   HAEMATOLOGICA

Incidence and Clinical Complications of Myelodysplastic Syndromes Among United States Medicare Beneficiaries

(2010) Stuart L. Goldberg et al.   JOURNAL OF CLINICAL ONCOLOGY

WHO-defined ‘myelodysplastic syndrome with isolated del(5q)’ in 88 consecutive patients: survival data, leukemic transformation rates and prevalence of JAK2, MPL and IDH mutations

(2010) M M Patnaik et al.   LEUKEMIA

Impact of adjunct cytogenetic abnormalities for prognostic stratification in patients with myelodysplastic syndrome and deletion 5q

(2010) M Mallo et al.   LEUKEMIA

Lenalidomide induces cell death in an MDS-derived cell line with deletion of chromosome 5q by inhibition of cytokinesis

(2010) A Matsuoka et al.   LEUKEMIA

FISH analysis of circulating CD34+ cells as a new tool for genetic monitoring in MDS: Verification of the method and application to 27 MDS patients

(2010) Friederike Braulke et al.   LEUKEMIA RESEARCH

Persistent Malignant Stem Cells in del(5q) Myelodysplasia in Remission

(2010) Ramin Tehranchi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Patients with del(5q) MDS who fail to achieve sustained erythroid or cytogenetic remission after treatment with lenalidomide have an increased risk for clonal evolution and AML progression

(2009) Gudrun Göhring et al.   ANNALS OF HEMATOLOGY

The heterogeneous prognosis of patients with myelodysplastic syndrome and chromosome 5 abnormalities

(2009) Hagop Kantarjian et al.   CANCER

Effect of lenalidomide therapy on hematopoiesis of patients with myelodysplastic syndrome associated with chromosome 5q deletion

(2009) M. Ximeri et al.   HAEMATOLOGICA

A p53-dependent mechanism underlies macrocytic anemia in a mouse model of human 5q– syndrome

(2009) Jillian L Barlow et al.   NATURE MEDICINE

Identification of miR-145 and miR-146a as mediators of the 5q– syndrome phenotype

(2009) Daniel T Starczynowski et al.   NATURE MEDICINE

5q– myelodysplastic syndromes: chromosome 5q genes direct a tumor-suppression network sensing actin dynamics

(2009) K M Eisenmann et al.   ONCOGENE

Loss of RhoB Expression Enhances the Myelodysplastic Phenotype of Mammalian Diaphanous-Related Formin mDia1 Knockout Mice

(2009) Aaron D. DeWard et al.   PLoS One

A critical role for phosphatase haplodeficiency in the selective suppression of deletion 5q MDS by lenalidomide

(2009) S. Wei et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Npm1 is a haploinsufficient suppressor of myeloid and lymphoid malignancies in the mouse

(2008) P. Sportoletti et al.   BLOOD

Relationship of Treatment-Related Cytopenias and Response to Lenalidomide in Patients With Lower-Risk Myelodysplastic Syndromes

(2008) Mikkael A. Sekeres et al.   JOURNAL OF CLINICAL ONCOLOGY

Treatment of myelodysplastic syndromes with 5q deletion before the lenalidomide era; the GFM experience with EPO and thalidomide

(2008) C. Kelaidi et al.   LEUKEMIA RESEARCH

The anti-cancer drug lenalidomide inhibits angiogenesis and metastasis via multiple inhibitory effects on endothelial cell function in normoxic and hypoxic conditions

(2008) Ling Lu et al.   MICROVASCULAR RESEARCH

Identification of RPS14 as a 5q- syndrome gene by RNA interference screen

(2008) Benjamin L. Ebert et al.   NATURE